Qt分散は,進行性閉塞性心不全および左心室内静脈機能低下の患者に対する予後情報を持っていません
1Copenhagen University Hospital, Gentofte, Denmark.
Circulation
|February 15, 2001
まとめ
QT分散は,進行性閉塞性心不全 (CHF) の患者の死亡率を予測しません. この研究では,QT分散と全因,心臓,または心律不全の死亡との間に,CHF患者における関連性が見つかりませんでした.
科学分野:
- 心臓病学 心臓病学
- 電気生理学 電気生理学
- 心不全に関する研究
背景:
- QT分散は,タキアリズムイベントと死亡率の潜在的な予後マーカーです.
- 閉塞性心不全 (CHF) の患者におけるその予後値は不明である.
研究 の 目的:
- 進行性CHFと左心室機能不全の患者におけるQT分散の予後値を調査する.
主な方法:
- Diamond-CHF研究における,進行したCHFを患った703人の患者からのベースラインEKGの分析.
- フォローアップ期間の中央は18ヶ月で,全因,心疾患,心律失調による死亡率を評価した.
- QT分散から得られた予後情報を決定するための生存分析.
主要な成果:
- 中央のQT分散は70msで,生存者と生存者間の有意な違いはありませんでした.
- QT分散は,あらゆる原因による死亡率の予後値を示さなかった (P=0.74).
- QT分散は心臓の死亡率 (P=0.55) や心律不整の死亡率 (P=0.38) を予測しなかった.
結論:
- QT分散は,進行したCHFと左心室内静脈機能の低下を有する患者の死亡結果の予後値に欠けている.
関連する概念動画
Cardiomyopathy II: Dilated Cardiomyopathy
107
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
107
Heart Failure VI: Adjunct Therapies
68
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
Heart Failure IV: Classification and Diagnostic Evaluation
93
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
93
Mitral Stenosis II: Clinical features and Diagnostic Tests
61
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
61
Heart Failure Drugs: Diuretics
575
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
575


